Navigation Links
ThromboGenics Announces Results From a Phase IIa Trial Evaluating Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
Date:10/5/2009

s is a biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of eye disease, vascular disease and cancer. The Company's lead product microplasmin is in Phase III clinical development for the non-surgical treatment of back of the eye diseases. Microplasmin is also being evaluated in Phase II clinical development for additional vitreoretinal conditions. In addition, ThromboGenics is developing novel antibody therapeutics in collaboration with BioInvent International; these include TB-402 (Anti-Factor VIII), a long acting anti-coagulant, and TB-403 (anti-PlGF) for cancer.

ThromboGenics has built strong links with the University of Leuven and the Flanders Institute for Biotechnology (VIB) and has exclusive rights to certain therapeutics developed at these institutions. ThromboGenics is headquartered in Leuven, Belgium. The Company is listed on Eurolist by Euronext Brussels under the symbol THR. More information is available at http://www.thrombogenics.com.

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report.

    For further information please contact:

    ThromboGenics
    Dr. Steve Pakola, CMO
    Tel: +
'/>"/>
SOURCE  ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 

Related biology technology :

1. ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007
2. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
3. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
4. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
5. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
6. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
7. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
8. ThromboGenics Announces 2007 Full Year Results
9. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
10. ThromboGenics N.V. - Business Update
11. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... , May 17, 2013  Cellular Biomedicine ... achieved 50% enrollment of the total projected enrollment ... the safety and preliminary efficacy of the medical ... for Knee Osteoarthritis (KOA). To date the trial ... The Phase I open label clinical ...
(Date:5/17/2013)... 17, 2013  Insero Health, Inc., a company developing ... and related neurological disorders, is today reporting top-line results ... INS001 in patients with drug-resistant epilepsy.  The data are ... (AED) Xll meeting by Dr. Steven Schachter ... Insero,s Scientific Advisory Board.  In this study, INS001 appeared ...
(Date:5/17/2013)... May 17, 2013 RURO Inc. ... version 4.1, a versatile refinement to the smart ... solution, improves its advanced methodical management for transgenic ... ezColony 4.1. The network-based platform provides user access ... research. While continuing to emphasize streamlined tasks, such ...
(Date:5/17/2013)... 2013 Tooth decay is an epidemic in ... of the disease. The World Health Organization says that worldwide, ... adults have cavities. What are the long-term effects of this ... strong connection between the oral bacterial imbalance and serious systemic ... rampant, yet it is also 100% preventable? Answer: there has ...
Breaking Biology Technology:Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis 2Insero Health Reports Positive Data on Phase I Trial of Novel Therapy for Drug-resistant Epilepsy 2RURO Introduces ezColony 4.1 – The Versatile Transgenic Animal Colony Management Software 2Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay 2Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay 3
... April 18 FASgen, Inc. presented at the ... on FAS31, FASgen,s lead,compound for ovarian cancer. FAS31 ... enzyme that is highly expressed in many human ... is cytotoxic to a,variety of human xenograft models ...
... Inc. (Nasdaq:,EVVV) will release its 2008 first quarter financial ... hours., The company will host a conference call ... a.m. ET). ev3 management will review its first quarter,operating ... answer,session., The conference call will be available to ...
... BrainCells Inc. (BCI), a,biopharmaceutical company utilizing its ... the growth of new neurons for the treatment,of ... it raised an,additional $20 million in an extension ... $50 million. New investor, New Enterprise Associates (NEA),along ...
Cached Biology Technology:FASgen, Inc. Presents Ovarian Cancer Efficacy and Toxicology Data to the American Association for Cancer Research 2REVISED: BrainCells Inc. Expands Series B Financing to $50 Million 2
(Date:5/16/2013)... May 16, 2013 Integrated Biometrics patented ... a custom thin film transistor camera introduces Sherlock, ... roll image in the smallest and lightest form ... Appendix F Mobile ID FAP 45, Certified scanner ... in size and weight when compared to optical ...
(Date:5/16/2013)... where the entirety of an individual,s DNA is examined ... can cause health problems is a massively useful technology ... major ethical problems if used incorrectly, say new recommendations ... on line today (16 May 2013) in the ... on whole genome and on exome* sequencing and analysis ...
(Date:5/16/2013)... , May 16, 2013 Reportlinker.com ... is available in its catalogue: ... Opportunities, 2018 http://www.reportlinker.com/p01181929/Global-Biometric-Systems-Market-Forecast--Opportunities-2018.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Security_Systems ... old security practises such as photographs, passwords ... of biometric technologies in last few years. ...
Breaking Biology News(10 mins):European Society of Human Genetics urges caution over use of new genetic sequencing techniques 2Global Biometric Systems Market Forecast & Opportunities, 2018 2Global Biometric Systems Market Forecast & Opportunities, 2018 3Global Biometric Systems Market Forecast & Opportunities, 2018 4Global Biometric Systems Market Forecast & Opportunities, 2018 5Global Biometric Systems Market Forecast & Opportunities, 2018 6Global Biometric Systems Market Forecast & Opportunities, 2018 7
... the heart that can cause congestive heart failure. ... of the myocardium to regenerate and self-repair. Douglas ... the existence of a previously unrecognized subset of ... for myocardial tissue regeneration following myocardial infarction. , ...
... The World Health Organization (WHO) warned about increased ... dengue fever across tsunami-affected areas in Southeast Asia. ... region on 26 December, the organization is strengthening ... for mosquito vectors to multiply to sufficient levels, ...
... chemical has been found by Health Canada and the ... especially canned or bottled foods. A new study by ... Perez Locas explains the presence of this chemical in ... published in the October, 2004 issue of Journal of ...
Cached Biology News:WHO Warns Of Increased Risk Of Vector-borne Diseases In Tsunami-affected Areas 2WHO Warns Of Increased Risk Of Vector-borne Diseases In Tsunami-affected Areas 3WHO Warns Of Increased Risk Of Vector-borne Diseases In Tsunami-affected Areas 4